Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Filgrastim (r-metHuG-CSF) in the 21st century: SD/01.

Morstyn G, Foote MA, Walker T, Molineux G.

Acta Haematol. 2001;105(3):151-5. Review.

PMID:
11463988
2.

Hematopoietic growth factors in cancer chemotherapy.

Crawford J, Foote M, Morstyn G.

Cancer Chemother Biol Response Modif. 1999;18:250-67. Review.

PMID:
10800487
3.

Hematopoietic growth factors in cancer chemotherapy.

Lieschke GJ, Foote M, Morstyn G.

Cancer Chemother Biol Response Modif. 1997;17:363-89. Review. No abstract available.

PMID:
9551221
4.

Clinical benefits of improving host defences with rHuG-CSF.

Morstyn G, Foote M, Nelson S.

Ciba Found Symp. 1997;204:78-85; discussion 85-7.

PMID:
9107412
5.

Filgrastim (r-metHuG-CSF): the first 10 years.

Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G.

Blood. 1996 Sep 15;88(6):1907-29. Review. No abstract available.

PMID:
8822908
6.

Hematopoietic growth factors in cancer chemotherapy.

Morstyn G, Foote M, Lieschke GJ.

Cancer Chemother Biol Response Modif. 1996;16:295-314. Review. No abstract available.

PMID:
8639388
7.

Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial.

Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, Sheridan WP, Kefford RF, Cebon J, Olver I, McKendrick J, Toner G, Bradstock K, Lieschke M, Cruickshank S, Tomita DK, Hoffman EW, Fox RM, Morstyn G.

Ann Intern Med. 1994 Oct 1;121(7):492-501.

PMID:
7520676
8.

Stem cell factor is a potent synergistic factor in hematopoiesis.

Morstyn G, Brown S, Gordon M, Crawford J, Demetri G, Rich W, McGuire B, Foote M, McNiece I.

Oncology. 1994 Mar-Apr;51(2):205-14. Review.

PMID:
7515171
9.

Protection from lethal irradiation by the combination of stem cell factor and tempol.

Liebmann J, DeLuca AM, Epstein A, Steinberg SM, Morstyn G, Mitchell JB.

Radiat Res. 1994 Mar;137(3):400-4.

PMID:
7511822
10.

Endogenous haemopoietic growth factors in neutropenia and infection.

Cebon J, Layton JE, Maher D, Morstyn G.

Br J Haematol. 1994 Feb;86(2):265-74.

PMID:
7515265
11.

Hematopoietic growth factors in cancer chemotherapy.

Morstyn G, Lieschke GJ.

Cancer Chemother Biol Response Modif. 1994;15:367-90. Review. No abstract available.

PMID:
7540031
12.

Clinical applications of filgrastim and stem cell factor in vivo and in vitro.

Morstyn G, Glaspy J, Shpall EJ, LeMaistre F, Briddell R, Menchaca D, Lill M, Jones RB, Tami J, Brown S, et al.

J Hematother. 1994 Winter;3(4):353-5. Review. No abstract available.

PMID:
7537611
13.

The clinical utility of granulocyte colony-stimulating factor: early achievements and future promise.

Morstyn G, Foote M, Perkins D, Vincent M.

Stem Cells. 1994;12 Suppl 1:213-27; discussion 227-8. Review.

PMID:
7535147
14.

Recombinant methionyl human granulocyte colony-stimulating factor for the prevention and treatment of non-neutropenic infectious diseases.

Daifuku R, Andresen J, Morstyn G.

J Antimicrob Chemother. 1993 Jul;32 Suppl A:91-7. Review.

PMID:
7691789
15.

Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.

Grigg A, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath KM, Morstyn G, Fox RM, Sheridan WP.

Bone Marrow Transplant. 1993;11 Suppl 2:23-9.

PMID:
8334435
16.

Hematopoietic growth factors in cancer chemotherapy.

Morstyn G, Sheridan WP.

Cancer Chemother Biol Response Modif. 1993;14:353-70. Review. No abstract available.

PMID:
8312108
17.

Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation.

Lieschke GJ, Ramenghi U, O'Connor MP, Sheridan W, Szer J, Morstyn G.

Br J Haematol. 1992 Nov;82(3):589-95.

PMID:
1283080
18.

Clinical uses of growth factors.

Davis I, Morstyn G.

Baillieres Clin Haematol. 1992 Jul;5(3):753-86. Review.

PMID:
1457968
19.

Delay by internists in obtaining diagnostic biopsies in patients with suspected cancer.

Farag SS, Green MD, Morstyn G, Sheridan WP, Fox RM.

Ann Intern Med. 1992 Mar 15;116(6):473-8.

PMID:
1310838
20.

Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.

Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath KM, Morstyn G, Fox RM.

Lancet. 1992 Mar 14;339(8794):640-4.

PMID:
1371817
21.

Marrow proliferation and the appearance of giant neutrophils in response to recombinant human granulocyte colony stimulating factor (rhG-CSF).

Campbell LJ, Maher DW, Tay DL, Boyd AW, Rockman S, McGrath K, Fox RM, Morstyn G.

Br J Haematol. 1992 Mar;80(3):298-304.

PMID:
1374626
22.

The dissociation of GM-CSF efficacy from toxicity according to route of administration: a pharmacodynamic study.

Cebon J, Lieschke GJ, Bury RW, Morstyn G.

Br J Haematol. 1992 Feb;80(2):144-50.

PMID:
1550769
23.

Carboplatin-containing regimens for small cell lung cancer: implications for management in the elderly.

Raghavan D, Bishop JF, Stuart-Harris R, Zalcberg J, Morstyn G, Kefford RF, Matthews JP.

Semin Oncol. 1992 Feb;19(1 Suppl 2):12-6.

PMID:
1329217
24.

Colony-stimulating factors in cancer therapy.

Morstyn G, Sheridan WP.

Cancer Chemother Biol Response Modif. 1992;13:308-26. Review. No abstract available.

PMID:
1382528
25.
26.

G-CSF mobilised progenitor cells in autologous transplantation: in vitro and in vivo aspects.

Begley CG, DeLuca E, Rowlings PA, Szer J, Watson D, Juttner C, Morstyn G, Fox RM, Sheridan W.

J Nutr Sci Vitaminol (Tokyo). 1992;Spec No:368-71.

PMID:
1284309
27.

Identification of a functional domain of human granulocyte colony-stimulating factor using neutralizing monoclonal antibodies.

Layton JE, Morstyn G, Fabri LJ, Reid GE, Burgess AW, Simpson RJ, Nice EC.

J Biol Chem. 1991 Dec 15;266(35):23815-23.

28.

Clinical profile in Barrett's esophagus: who should be screened for cancer?

Collins BJ, Abbott M, Thomas RJ, Morstyn G, St John DJ.

Hepatogastroenterology. 1991 Aug;38(4):341-4.

PMID:
1937380
29.

The role of granulocyte colony-stimulating factor in cancer chemotherapy.

Davis I, Morstyn G.

Semin Hematol. 1991 Apr;28(2 Suppl 2):25-33. Review. No abstract available.

PMID:
1712124
30.

Characterisation of a cell line (LCC-18) from a cultured human neuroendocrine-differentiated colonic carcinoma.

Lundqvist M, Mark J, Funa K, Heldin NE, Morstyn G, Wedell B, Layton J, Oberg K.

Eur J Cancer. 1991;27(12):1663-8.

PMID:
1782079
31.

Human interleukin-4: an immunomodulator with potential therapeutic applications.

Maher DW, Davis I, Boyd AW, Morstyn G.

Prog Growth Factor Res. 1991;3(1):43-56. Review.

PMID:
1777599
32.

The role of colony stimulating factors in cancer therapy.

Morstyn G, Sheridan WP.

Cancer Chemother Biol Response Modif. 1991;12:307-26. Review. No abstract available.

PMID:
1718376
33.

Monoclonal antibodies that recognize human granulocyte-macrophage colony-stimulating factor and neutralize its bioactivity in vitro.

Dempsey PJ, Layton JE, Duhrsen U, Nicola NA, Cebon J, Burgess AW, Morstyn G.

Hybridoma. 1990 Dec;9(6):545-58.

PMID:
1706312
34.

Pharmacokinetics and toxicity of two schedules of high dose epirubicin.

Tjuljandin SA, Doig RG, Sobol MM, Watson DM, Sheridan WP, Morstyn G, Mihaly G, Green MD.

Cancer Res. 1990 Aug 15;50(16):5095-101.

35.

The impact of colony stimulating factors on cancer chemotherapy.

Morstyn G.

Br J Haematol. 1990 Jul;75(3):303-7. Review. No abstract available.

PMID:
1696832
36.

Granulocyte-macrophage colony stimulating factor from human lymphocytes. The effect of glycosylation on receptor binding and biological activity.

Cebon J, Nicola N, Ward M, Gardner I, Dempsey P, Layton J, Dührsen U, Burgess AW, Nice E, Morstyn G.

J Biol Chem. 1990 Mar 15;265(8):4483-91.

37.

Selective uptake of hematoporphyrin derivative into human cerebral glioma.

Hill JS, Kaye AH, Sawyer WH, Morstyn G, Megison PD, Stylli SS.

Neurosurgery. 1990 Feb;26(2):248-54.

PMID:
2137904
38.
39.
40.
41.

Towards improved cancer therapy using subcutaneously administered hemopoietic colony stimulating factors.

Morstyn G, Sheridan W, Lieschke G, Cebon J, Layton J, Fox R.

Prog Clin Biol Res. 1990;354B:29-36. Review. No abstract available.

PMID:
1700441
42.

Human granulocyte-macrophage colony-stimulating factor (hGM-CSF): identification of a binding site for a neutralizing antibody.

Nice E, Dempsey P, Layton J, Morstyn G, Cui DF, Simpson R, Fabri L, Burgess A.

Growth Factors. 1990;3(2):159-69.

PMID:
1698402
44.

Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation.

Sheridan WP, Morstyn G, Wolf M, Dodds A, Lusk J, Maher D, Layton JE, Green MD, Souza L, Fox RM.

Lancet. 1989 Oct 14;2(8668):891-5.

PMID:
2477656
45.

Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy.

Morstyn G, Campbell L, Lieschke G, Layton JE, Maher D, O'Connor M, Green M, Sheridan W, Vincent M, Alton K, et al.

J Clin Oncol. 1989 Oct;7(10):1554-62.

PMID:
2789274
46.
47.

Pharmacology of the colony-stimulating factors.

Morstyn G, Lieschke GJ, Sheridan W, Layton J, Cebon J.

Trends Pharmacol Sci. 1989 Apr;10(4):154-9. Review.

PMID:
2665248
48.

Diffuse large cell lymphoma: a teaching hospital experience.

Marks DI, Sheridan WP, Ellis DW, Boyd AW, Morstyn G, Green MD, Fox RM.

Aust N Z J Med. 1989 Apr;19(2):159-61. No abstract available. Erratum in: Aust N Z J Med 1989 Aug;19(4):357.

PMID:
2475099
49.

Clinical experience with recombinant human granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor.

Morstyn G, Lieschke GJ, Sheridan W, Layton J, Cebon J, Fox RM.

Semin Hematol. 1989 Apr;26(2 Suppl 2):9-13.

PMID:
2471275
50.

Empiric single agent or combination antibiotic therapy for febrile episodes in neutropenic patients: an overview.

Lieschke GJ, Bell D, Rawlinson W, Green MD, Sheridan W, Morstyn G, Stuart-Harris R, Kefford RF, Levi J, Sorrell T, et al.

Eur J Cancer Clin Oncol. 1989;25 Suppl 2:S37-42. Review.

PMID:
2693108

Supplemental Content

Loading ...
Support Center